Envista (NYSE:NVST) Downgraded by Wall Street Zen to "Hold"

Key Points

• Wall Street Zen downgraded Envista from “Buy” to “Hold.” The broader analyst consensus is also “Hold,” with an average price target of $29.
• Envista beat quarterly estimates, reporting earnings of $0.40 per share versus $0.36 expected and revenue of $691.5 million versus $688.74 million expected; revenue grew 3.2% year over year.
• Other analysts showed mixed views: Piper Sandler and BMO lowered their price targets to $26, while Leerink Partners cut its target to $32 but maintained an “Outperform” rating.

Envista (NYSE:NVST - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Several other analysts have also recently weighed in on NVST. Needham & Company LLC reaffirmed a "hold" rating on shares of Envista in a research note on Thursday. Piper Sandler decreased their price objective on shares of Envista from $28.00 to $26.00 and set a "neutral" rating for the company in a report on Friday, October 9th. Zacks Research lowered Envista from a "strong-buy" rating to a "hold" rating in a research note on Monday, October 5th. Leerink Partners lowered their price target on Envista from $35.00 to $32.00 and set an "outperform" rating on the stock in a research report on Wednesday, October 14th. Finally, BMO Capital Markets cut their price objective on shares of Envista from $29.00 to $26.00 and set a "market perform" rating on the stock in a report on Monday, September 28th. Six investment analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company. Based on data from MarketBeat, Envista currently has a consensus rating of "Hold" and an average price target of $29.00.

Envista Trading Up 0.9%

Envista stock opened at $25.20 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.07 and a current ratio of 2.43. The stock has a market cap of $4.05 billion, a PE ratio of 6.51, a price-to-earnings-growth ratio of 1.26 and a beta of 0.94. The stock has a 50-day moving average of $24.38 and a two-hundred day moving average of $25.74. Envista has a one year low of $18.77 and a one year high of $30.42.

Envista (NYSE:NVST - Get Free Report) last posted its earnings results on Wednesday, November 4th. The company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.36 by $0.04. Envista had a net margin of 3.33% and a return on equity of 7.88%. The firm had revenue of $691.50 million during the quarter, compared to the consensus estimate of $688.74 million. During the same quarter last year, the firm earned $0.32 EPS. The firm's revenue for the quarter was up 3.2% on a year-over-year basis. On average, research analysts anticipate that Envista will post 1.54 EPS for the current fiscal year.

Insider Buying and Selling

In other Envista news, SVP Mischa Reis sold 8,000 shares of the business's stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $27.50, for a total transaction of $220,000.00. Following the sale, the senior vice president owned 27,321 shares of the company's stock, valued at $751,327.50. The trade was a 22.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.99% of the stock is owned by insiders.

Institutional Investors Weigh In On Envista

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NVST. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Envista in the second quarter worth about $25,000. Provenance Wealth Advisors LLC bought a new position in Envista in the third quarter valued at approximately $28,000. Nisa Investment Advisors LLC increased its stake in shares of Envista by 116.4% in the third quarter. Nisa Investment Advisors LLC now owns 1,679 shares of the company's stock valued at $39,000 after buying an additional 903 shares during the period. Nykredit A S bought a new stake in Envista in the 2nd quarter valued at about $52,000. Finally, C M Bidwell & Associates Ltd. purchased a new stake in shares of Envista in the second quarter valued at about $63,000.

Trending Headlines about Envista

Here are the key news stories impacting Envista this week:

• Positive Sentiment: Q3 results topped expectations: Envista reported adjusted earnings of $0.40 per share and revenue of $691.5 million, both above analyst estimates. Revenue rose 3.2% year over year, while earnings increased from $0.32 a year earlier. Envista tops Q3 earnings and revenue estimates
• Positive Sentiment: 2026 outlook raised: Management lifted its earnings outlook, citing pricing and productivity gains—an encouraging signal for near-term profitability. Q3 earnings-call highlights
• Positive Sentiment: UBS raised its price target from $27 to $29, though it maintained a Neutral rating. UBS Group stock recommendations
• Neutral Sentiment: Some valuation commentary argues NVST may be undervalued following a substantial prior decline, while a Zacks article highlights its momentum score. These are analyst perspectives rather than new company developments. Envista could be undervalued on earnings guidance
• Negative Sentiment: China remains a forward-looking risk: Procurement reforms there could weigh on margins as Envista enters 2027, potentially offsetting some benefits from pricing and productivity improvements. Q3 earnings-call highlights

About Envista

Envista Holdings Corporation NYSE: NVST is a global dental products and technologies company headquartered in Brea, California. The company develops, manufactures and markets products used by dentists, dental specialists, dental laboratories and other oral health professionals.

Envista's portfolio includes dental implants, orthodontic systems, digital imaging and workflow solutions, dental consumables, treatment equipment and related technologies. Its brands include Nobel Biocare, Ormco, DEXIS and Kerr, which provide products and services spanning implant dentistry, orthodontics, diagnostic imaging, restorative care and general dental practice management.

Envista was established as an independent public company in 2019 following its separation from Danaher Corporation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.